Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity
Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kuniaki Tsutsumi [verfasserIn] Takanori Kaname [verfasserIn] Haruka Shiraishi [verfasserIn] Takehiro Kawashiri [verfasserIn] Nobuaki Egashira [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Journal of Pharmacological Sciences - Elsevier, 2017, 131(2016), 2, Seite 146-149 |
|---|---|
| Übergeordnetes Werk: |
volume:131 ; year:2016 ; number:2 ; pages:146-149 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jphs.2016.04.019 |
|---|
| Katalog-ID: |
DOAJ026384787 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ026384787 | ||
| 003 | DE-627 | ||
| 005 | 20230307101251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jphs.2016.04.019 |2 doi | |
| 035 | |a (DE-627)DOAJ026384787 | ||
| 035 | |a (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Kuniaki Tsutsumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. | ||
| 650 | 4 | |a Paclitaxel | |
| 650 | 4 | |a Peripheral neuropathy | |
| 650 | 4 | |a Polaprezinc | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Takanori Kaname |e verfasserin |4 aut | |
| 700 | 0 | |a Haruka Shiraishi |e verfasserin |4 aut | |
| 700 | 0 | |a Takehiro Kawashiri |e verfasserin |4 aut | |
| 700 | 0 | |a Nobuaki Egashira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pharmacological Sciences |d Elsevier, 2017 |g 131(2016), 2, Seite 146-149 |w (DE-627)1760631620 |x 13478613 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2016 |g number:2 |g pages:146-149 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jphs.2016.04.019 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1347861316300366 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1347-8613 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2016 |e 2 |h 146-149 | ||
| author_variant |
k t kt t k tk h s hs t k tk n e ne |
|---|---|
| matchkey_str |
article:13478613:2016----::oarznrdcsaltxlnueprpeanuoahirtwtot |
| hierarchy_sort_str |
2016 |
| callnumber-subject-code |
RM |
| publishDate |
2016 |
| allfields |
10.1016/j.jphs.2016.04.019 doi (DE-627)DOAJ026384787 (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b DE-627 ger DE-627 rakwb eng RM1-950 Kuniaki Tsutsumi verfasserin aut Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. Paclitaxel Peripheral neuropathy Polaprezinc Therapeutics. Pharmacology Takanori Kaname verfasserin aut Haruka Shiraishi verfasserin aut Takehiro Kawashiri verfasserin aut Nobuaki Egashira verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 131(2016), 2, Seite 146-149 (DE-627)1760631620 13478613 nnns volume:131 year:2016 number:2 pages:146-149 https://doi.org/10.1016/j.jphs.2016.04.019 kostenfrei https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861316300366 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 131 2016 2 146-149 |
| spelling |
10.1016/j.jphs.2016.04.019 doi (DE-627)DOAJ026384787 (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b DE-627 ger DE-627 rakwb eng RM1-950 Kuniaki Tsutsumi verfasserin aut Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. Paclitaxel Peripheral neuropathy Polaprezinc Therapeutics. Pharmacology Takanori Kaname verfasserin aut Haruka Shiraishi verfasserin aut Takehiro Kawashiri verfasserin aut Nobuaki Egashira verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 131(2016), 2, Seite 146-149 (DE-627)1760631620 13478613 nnns volume:131 year:2016 number:2 pages:146-149 https://doi.org/10.1016/j.jphs.2016.04.019 kostenfrei https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861316300366 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 131 2016 2 146-149 |
| allfields_unstemmed |
10.1016/j.jphs.2016.04.019 doi (DE-627)DOAJ026384787 (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b DE-627 ger DE-627 rakwb eng RM1-950 Kuniaki Tsutsumi verfasserin aut Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. Paclitaxel Peripheral neuropathy Polaprezinc Therapeutics. Pharmacology Takanori Kaname verfasserin aut Haruka Shiraishi verfasserin aut Takehiro Kawashiri verfasserin aut Nobuaki Egashira verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 131(2016), 2, Seite 146-149 (DE-627)1760631620 13478613 nnns volume:131 year:2016 number:2 pages:146-149 https://doi.org/10.1016/j.jphs.2016.04.019 kostenfrei https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861316300366 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 131 2016 2 146-149 |
| allfieldsGer |
10.1016/j.jphs.2016.04.019 doi (DE-627)DOAJ026384787 (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b DE-627 ger DE-627 rakwb eng RM1-950 Kuniaki Tsutsumi verfasserin aut Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. Paclitaxel Peripheral neuropathy Polaprezinc Therapeutics. Pharmacology Takanori Kaname verfasserin aut Haruka Shiraishi verfasserin aut Takehiro Kawashiri verfasserin aut Nobuaki Egashira verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 131(2016), 2, Seite 146-149 (DE-627)1760631620 13478613 nnns volume:131 year:2016 number:2 pages:146-149 https://doi.org/10.1016/j.jphs.2016.04.019 kostenfrei https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861316300366 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 131 2016 2 146-149 |
| allfieldsSound |
10.1016/j.jphs.2016.04.019 doi (DE-627)DOAJ026384787 (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b DE-627 ger DE-627 rakwb eng RM1-950 Kuniaki Tsutsumi verfasserin aut Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. Paclitaxel Peripheral neuropathy Polaprezinc Therapeutics. Pharmacology Takanori Kaname verfasserin aut Haruka Shiraishi verfasserin aut Takehiro Kawashiri verfasserin aut Nobuaki Egashira verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 131(2016), 2, Seite 146-149 (DE-627)1760631620 13478613 nnns volume:131 year:2016 number:2 pages:146-149 https://doi.org/10.1016/j.jphs.2016.04.019 kostenfrei https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861316300366 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 131 2016 2 146-149 |
| language |
English |
| source |
In Journal of Pharmacological Sciences 131(2016), 2, Seite 146-149 volume:131 year:2016 number:2 pages:146-149 |
| sourceStr |
In Journal of Pharmacological Sciences 131(2016), 2, Seite 146-149 volume:131 year:2016 number:2 pages:146-149 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Paclitaxel Peripheral neuropathy Polaprezinc Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Journal of Pharmacological Sciences |
| authorswithroles_txt_mv |
Kuniaki Tsutsumi @@aut@@ Takanori Kaname @@aut@@ Haruka Shiraishi @@aut@@ Takehiro Kawashiri @@aut@@ Nobuaki Egashira @@aut@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
1760631620 |
| id |
DOAJ026384787 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ026384787</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307101251.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jphs.2016.04.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ026384787</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf7573b8aee2a406482c7393c09affe3b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kuniaki Tsutsumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Paclitaxel</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peripheral neuropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polaprezinc</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takanori Kaname</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haruka Shiraishi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">131(2016), 2, Seite 146-149</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:146-149</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jphs.2016.04.019</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861316300366</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2016</subfield><subfield code="e">2</subfield><subfield code="h">146-149</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Kuniaki Tsutsumi |
| spellingShingle |
Kuniaki Tsutsumi misc RM1-950 misc Paclitaxel misc Peripheral neuropathy misc Polaprezinc misc Therapeutics. Pharmacology Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| authorStr |
Kuniaki Tsutsumi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760631620 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| issn |
13478613 |
| topic_title |
RM1-950 Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity Paclitaxel Peripheral neuropathy Polaprezinc |
| topic |
misc RM1-950 misc Paclitaxel misc Peripheral neuropathy misc Polaprezinc misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc Paclitaxel misc Peripheral neuropathy misc Polaprezinc misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc Paclitaxel misc Peripheral neuropathy misc Polaprezinc misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Pharmacological Sciences |
| hierarchy_parent_id |
1760631620 |
| hierarchy_top_title |
Journal of Pharmacological Sciences |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760631620 |
| title |
Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| ctrlnum |
(DE-627)DOAJ026384787 (DE-599)DOAJf7573b8aee2a406482c7393c09affe3b |
| title_full |
Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| author_sort |
Kuniaki Tsutsumi |
| journal |
Journal of Pharmacological Sciences |
| journalStr |
Journal of Pharmacological Sciences |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| container_start_page |
146 |
| author_browse |
Kuniaki Tsutsumi Takanori Kaname Haruka Shiraishi Takehiro Kawashiri Nobuaki Egashira |
| container_volume |
131 |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kuniaki Tsutsumi |
| doi_str_mv |
10.1016/j.jphs.2016.04.019 |
| author2-role |
verfasserin |
| title_sort |
polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| callnumber |
RM1-950 |
| title_auth |
Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| abstract |
Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. |
| abstractGer |
Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. |
| abstract_unstemmed |
Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity |
| url |
https://doi.org/10.1016/j.jphs.2016.04.019 https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b http://www.sciencedirect.com/science/article/pii/S1347861316300366 https://doaj.org/toc/1347-8613 |
| remote_bool |
true |
| author2 |
Takanori Kaname Haruka Shiraishi Takehiro Kawashiri Nobuaki Egashira |
| author2Str |
Takanori Kaname Haruka Shiraishi Takehiro Kawashiri Nobuaki Egashira |
| ppnlink |
1760631620 |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.jphs.2016.04.019 |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T20:40:51.917Z |
| _version_ |
1803591878620217344 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ026384787</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307101251.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jphs.2016.04.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ026384787</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf7573b8aee2a406482c7393c09affe3b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kuniaki Tsutsumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Paclitaxel</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peripheral neuropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Polaprezinc</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takanori Kaname</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haruka Shiraishi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">131(2016), 2, Seite 146-149</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:146-149</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jphs.2016.04.019</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f7573b8aee2a406482c7393c09affe3b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861316300366</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2016</subfield><subfield code="e">2</subfield><subfield code="h">146-149</subfield></datafield></record></collection>
|
| score |
7.399457 |